Site Map
Japanese
Business Unit
Pipeline
Social Responsibility
Corporate profile
Our Message
Corporate governance
Operation
Corporate history
List of offices
Business Unit
Ohara Pharmaceutical:Our mission
Orphan drugs (pharmaceuticals for rare medical conditions) business
Generic drugs business
Corporate profile
Our Message
Corporate governance
Operation
Corporate history
List of offices
Entirely from the patients' perspective
Providing dependable pharmaceuticals
for the future of medicine
Ohara Pharmaceutical Co.,Ltd.
News Release
September 24, 2020
Recombinant Chimeric Monoclonal Antibody "Dinutuximab (OP-08)":Application Filed for Marketing Authorization for Neuroblastoma
August 17, 2020
Recombinant Chimeric Monoclonal Antibody “Dinutuximab (OP-08)” Receives Orphan Drug Designation for Neuroblastoma from MHLW
August 17, 2020
Glucarpidase (Genetical Recombination) “OP-07” Receives Orphan Drug Designation from MHLW
April 1, 2020
Initiation of a Phase I/II Clinical Study of “OP-10” in Japan
May 16, 2019
Announcement of a Strategic Capital and Business Alliance Agreement with Fidson Healthcare Plc.
View List
Childhood Cancer
Hepato/Biliary/Pancreatic
Parkinson’s disease
Business Unit
Responsibility
Corporate Profile
